| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Musculoskeletal System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Musculoskeletal System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Organogenesis Holdings Inc.$2.4
-0.06 (-2.44%)
D 36Pipeline Score MedTech · Clinical
Market Cap
342.27 M
EPS
-0.14
P/E Ratio
-
Value Trade
1.86 M
SEC Financials
Q1 2026Dilution Risk
Revenue
37.23 M
R&D Expenses
15.16 M
Operating CF
21.13 M
Total Assets
519.99 M
Total Liabilities
138.65 M
Equity
244.56 M
D/E Ratio
12,345
4.31 %
Week
9.47 %
1 Month
-32.83 %
3 Month
-48.25 %
6 Month
-83.47 %
5 Year
-72.99 %
All Time
Cash Data
Cash Position
91.38 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.34 M
52 Week Range
2.04 - 7.08
% held by Insiders
44.67 %
% held by Institutions
49.13 %
Enterprise Value
457.83 M
Total Shares
128.70 M
Short %
19.19 %
Float Shares
71.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Organogenesis Holdings Inc.
186Total events
4Upcoming
32Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 4
Event history 182
Jul 6, 2026
▲FDA Filing AcceptedReNuRegulatory Filing
FDA accepts BLA filing for ReNu
symptomatic knee osteoarthritissource ↗
Jul 6, 2026
Apr 28, 2026
▲Rolling Submission CompletedReNuRegulatory Filing
Completed rolling BLA submission for ReNu
symptomatic knee osteoarthritissource ↗
Apr 6, 2026
▲Primary Endpoint MetPuraPly®AMClinical Data
PuraPly®AM plus SOC achieved statistically significant wound closure at 12 weeks vs SOC alone (p<0.0477)
non-healing diabetic foot ulcerssource ↗
Apr 6, 2026
▲Type B MeetingReNuFDA Meeting
Successful Type-B meeting with FDA confirming rolling BLA submission plan
knee osteoarthritis painsource ↗
Q1 2026
●BLA SubmissionReNuRegulatory Filing
Completion of BLA submission with final modules
symptomatic knee osteoarthritissource ↗
Drug Pipeline Intelligence
D36
Pipeline Score $337M
Pipeline ValueValuation Signal
1
Drugs Scored1.0x
rNPV / MCap Top 49%
Micro Cap (rank 466 of 912)
Percentile RankOrganogenesis Holdings Inc. faces pipeline headwinds (36/100), with $842M risk-adjusted pipeline value, led by Amniotic Allograft in Knee Osteoarthritis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amniotic Allograft Monoclonal antibody | Knee Osteoarthritis | Phase 3 | NCT06000410 | 68% | $842M | COMPLETED | 1,110 | - | - | Nov 1, 2025 | - | Dec 22, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PuraPly®AM | non-healing diabetic foot ulcers | — | 2026-04-07 | statistically significant wound closure at 12 weeks, compared to SOC alone (p < 0.0477) Read More | Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM Read More | |
PuraPly®AM | non-healing diabetic foot ulcers | — | 2026-04-07 | statistically significant wound closure at 12 weeks, compared to SOC alone (p < 0.0477) Read More | Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM Read More | |
PuraPly®AM | non-healing diabetic foot ulcers | — | 2026-04-07 | statistically significant wound closure at 12 weeks, compared to SOC alone (p < 0.0477) Read More | Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ORGO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ORGO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ORGO▼ -2.4%today
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Organogenesis Holdings Inc. will report its financial results for the second quarter of fiscal year 2026 on August 6, 2026. The announcement includes a conference call scheduled for 5:00 p.m. ET on the same day, where management will discuss the results and provide a corporate update. The event will be accessible via webcast and teleconference.
Read more →ORGOOrganogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
Organogenesis Holdings Inc. announced that the FDA has accepted its Biologics License Application for ReNu, a treatment for symptomatic knee osteoarthritis. The FDA has set a target action date of April 24, 2027. ReNu is designed to be a non-surgical option for the millions suffering from knee OA pain, which affects an estimated 31 million Americans.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2026 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported a challenging first quarter for 2026, with net revenue falling to $36.3 million, a significant decrease from $86.7 million in the same period last year. The company experienced a net loss of $53.2 million, compared to a loss of $18.8 million in Q1 2025. Despite these setbacks, management remains optimistic about future market share growth in the second half of 2026, citing their extensive portfolio and the recent ReNu BLA submission as key supportive factors.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Organogenesis Holdings Inc. reported a significant decline in financial performance for Q1 2026, with net revenue dropping to $36.3 million, a decrease of 58% from the previous year. The company experienced a net loss of $53.2 million, compared to a loss of $18.8 million in Q1 2025. Despite these challenges, management remains optimistic about future market share gains and the long-term potential of their product portfolio.
Read more →ORGOOrganogenesis Completes Rolling Submission of Biologics License Application for ReNu®
Organogenesis Holdings Inc. has completed a rolling Biologics License Application (BLA) submission for ReNu®, a cryopreserved amniotic suspension allograft aimed at treating symptomatic knee osteoarthritis (OA). This submission marks a crucial step in bringing a new regenerative therapy to patients. The company is optimistic about its discussions with the FDA as it seeks approval for this innovative treatment.
Read more →ORGOOrganogenesis Holdings, Inc. Investigated by the Portnoy Law Firm
Organogenesis Holdings, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a significant drop in stock price. This decline, amounting to 10.14%, was prompted by a regulatory change announced by the Centers for Medicare & Medicaid Services affecting skin substitute grafts and related products. Analysts noted that the absence of key Local Coverage Determinations has intensified competition in an already crowded market, undermining investor confidence and projecting a concerning outlook for future revenues. The law firm is encouraging affected investors to reach out for legal recourse.
Read more →ORGOOrganogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Organogenesis Holdings Inc. announced the successful completion of a randomized controlled trial for PuraPly®AM, showing significant wound closure in diabetic foot ulcers compared to standard care. The trial involved 170 patients and achieved its primary endpoint, indicating the product's clinical efficacy. The company plans to publish these findings in a peer-reviewed journal, which may influence future coverage policies.
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Organogenesis Holdings Inc. will report its first quarter financial results for fiscal year 2026 on May 7, 2026. A conference call is scheduled for the same day at 5:00 p.m. Eastern Time to discuss these results and provide a corporate update. The call will also include a question and answer session for participants.
Read more →ORGOOrganogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain
Organogenesis Holdings Inc. has announced a successful Type-B meeting with the FDA, confirming plans to submit a rolling Biologics License Application (BLA) for its product ReNu by the end of 2025. This application targets the management of knee osteoarthritis, which affects millions in the U.S. The ReNu program is built on extensive clinical data and has received Regenerative Medicine Advanced Therapy designation. However, the path to commercial approval still carries significant uncertainties and risks.
Read more →ORGO▼ -10%on this news· ran to -30% by day 3
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
Organogenesis Holdings Inc. reported impressive financial results for the fourth quarter and full year of 2025, with net product revenue reaching $225.1 million, a 78% rise from the previous year. The substantial revenue growth was primarily driven by a notable increase in their Advanced Wound Care segment, which saw an 83% year-over-year revenue rise. Despite these achievements, there is concern about a 2% decline in revenue from Surgical & Sports Medicine products and expected short-term impacts in 2026 due to ongoing market adaptations to reform coverage and payment for skin substitutes.
Read more →ORGO▼ -10%on this news· ran to -30% by day 3
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue CANTON, Mass., (
Organogenesis Holdings Inc. reported strong financial results for the fourth quarter and fiscal year ended December 31, 2025, achieving record revenues and significant increases in net income and adjusted EBITDA. The fourth quarter saw net product revenue rise to $225.1 million, driven largely by the Advanced Wound Care segment, which reported an 83% increase. Despite these gains, the company faced a slight decline in revenue from Surgical & Sports Medicine products and anticipates market challenges ahead as it navigates reimbursement reforms in 2026. Overall, the outlook remains positive with a focus on long-term growth potential.
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Organogenesis Holdings Inc. announced that it will report its fourth quarter and fiscal year 2025 financial results on February 26, 2026, after the market closes. Following the release, management will host a conference call at 5:00 p.m. ET to discuss results and provide updates, including a question and answer session. This announcement highlights the company's ongoing commitment to providing insights into its financial performance and operations in the regenerative medicine sector.
Read more →ORGOOrganogenesis Announces Initiation of Biologics License Application for ReNu®
Organogenesis Holdings Inc. has initiated a rolling submission of a Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension allograft aimed at treating symptomatic knee osteoarthritis. The final modules of the BLA are expected to be submitted in the first half of 2026. If approved, ReNu would be the first non-surgical biologic therapy for knee OA, addressing a significant patient need.
Read more →ORGO▲ +7%on this news
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Organogenesis Holdings Inc. has successfully completed a Type-B meeting with the FDA, confirming the appropriateness of their clinical development program for ReNu, a treatment for knee osteoarthritis. The company plans to file a rolling Biologics License Application by the end of 2025. ReNu aims to meet the medical needs of millions affected by knee osteoarthritis.
Read more →ORGO▲ +44.7%on this news· ran to +68% by day 1
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
Organogenesis Holdings Inc. reported record revenue of $150.5 million for Q3 2025, marking a 31% increase from the previous year. The growth was primarily driven by strong sales in Advanced Wound Care and Surgical & Sports Medicine products. Despite a rise in operating expenses, the company remains optimistic about future performance, especially with new market opportunities on the horizon.
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance CANTON, Mass., (
Organogenesis Holdings Inc. has reported its financial results for the third quarter of 2025, showcasing a significant rise in net product revenue, hitting $150.5 million, reflecting a 31% increase compared to the same period in 2024. The net income also saw a considerable uplift, reaching $21.6 million in Q3 2025, which is a notable improvement from the previous year. The company plans to raise its fiscal guidance for 2025, influenced by a positive outlook on market opportunities due to changes in CMS payment rules.
Read more →ORGOOrganogenesis Applauds CMS’s Significant Step In Payment Reform
Organogenesis Holdings Inc. has praised the Centers for Medicare & Medicaid Services (CMS) for its recent payment reform for skin substitutes under the CY 2026 Physician Fee Schedule. The new policy aims to enhance access to PMA products and address issues in the existing system. CEO Gary S. Gillheeney expressed confidence that this reform will incentivize innovation and investment in regenerative medicine.
Read more →ORGO▼ -5.9%on this newsshared move
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Organogenesis Holdings Inc. announced inducement grants for Michael Catarina, its new Chief Technology Officer. The grants include non-statutory stock options for 82,542 shares and restricted stock units for 47,962 shares, both vesting over four years. These awards were made under Nasdaq Listing Rule 5635(c)(4) to incentivize Mr. Catarina's acceptance of the position.
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Organogenesis Holdings Inc. has announced that it will report its third quarter financial results for fiscal year 2025 on November 6, 2025. The report will be made public after market close, followed by a conference call at 5:00 p.m. Eastern Time for discussion and a Q&A session. This event underscores the company's ongoing commitment to transparency and engagement with its stakeholders.
Read more →ORGO▼ -12.4%on this newsshared move
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Organogenesis Holdings Inc. announced that its second Phase 3 trial of ReNu, a treatment for knee osteoarthritis, did not meet its primary endpoint for statistical significance. However, the trial showed a numerical improvement in pain reduction compared to the first Phase 3 trial. The company plans to seek a pre-BLA meeting with the FDA to discuss the submission pathway.
Read more →ORGO▲ +5.8%on this news
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
Organogenesis Holdings Inc. will participate in two major investor conferences in September 2025. The events include the Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference, both held in New York City. Webcasts of the sessions will be available on the company's website, providing access to investors and stakeholders.
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
Organogenesis Holdings Inc. reported its financial results for the second quarter of 2025, showing a net product revenue decrease to $100.8 million, down 23% from the previous year. Despite a reduction in net loss to $9.4 million, the company experienced a significant decline in revenue from its Advanced Wound Care products. However, Surgical & Sports Medicine products saw a 16% revenue increase. The CEO expressed optimism about upcoming policy changes expected to stabilize the industry.
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. has reported its financial results for the second quarter of 2025, indicating a significant decline in net product revenue which totaled $100.8 million, down from $130.2 million in the same period last year. Although the company experienced an improvement in net loss compared to Q2 2024, the adjusted net loss showed a notable decline, suggesting substantial operational challenges. Management remains optimistic about future industry policy changes and the potential of certain products, particularly ReNu for knee OA, which they believe could create new opportunities moving forward.
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
Organogenesis Holdings Inc. will report its second quarter financial results for fiscal year 2025 on August 7, 2025. The report will be released after market close, followed by a conference call at 5:00 p.m. ET. The call will include a discussion of the results and a Q&A session.
Read more →ORGO▼ -10.2%on this news
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
Organogenesis Holdings Inc. has praised the CMS's proposed payment reform for skin substitutes under the CY 2026 Physician Fee Schedule. The new payment structure is designed to ensure consistent payments across care settings while addressing concerns about Medicare spending. The company emphasizes the importance of clinical value in determining payment rates and is committed to refining the proposal to enhance patient access to necessary therapies.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported a significant decline in financial performance for the first quarter of 2025. Net revenue fell to $86.7 million, driven primarily by a 23% decrease in Advanced Wound Care product sales. The company also recorded a net loss of $18.8 million, a considerable increase compared to the previous year's loss. Despite these setbacks, the CEO expressed confidence in their commercial strategy and noted progress in product development initiatives.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
Organogenesis Holdings Inc. reported a significant decline in financial performance for the first quarter of 2025, with net revenue falling to $86.7 million, a decrease of 21% from the previous year. The company experienced a net loss of $18.8 million, greatly increasing from a $2.1 million loss in Q1 2024. Despite the challenges, there was an increase in revenue from the Surgical & Sports Medicine segment. Management remains optimistic about future developments and has reaffirmed revenue guidance for the year.
Read more →ORGO▲ +13.6%on this news
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness
Organogenesis Holdings Inc. has expressed support for the U.S. Centers for Medicare & Medicaid Services' decision to delay its local coverage determinations for skin substitute grafts aimed at treating diabetic foot ulcers and venous leg ulcers. The company emphasizes the importance of maintaining patient access to high-quality evidence-based products. While acknowledging this as a positive first step, Organogenesis advocates for an integrated coverage and payment policy to address the growing Medicare costs while ensuring effective patient care and innovation. The company's leadership in regenerative medicine over four decades further establishes its influence in the field.
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Organogenesis Holdings Inc. has announced that it will report its first quarter financial results for fiscal year 2025 on May 8, 2025. The announcement includes details about a conference call scheduled for the same day at 5:00 p.m. Eastern Time to discuss the results and provide a corporate update. The call will feature a question-and-answer session and will be accessible via webcast. This financial update underscores the company's ongoing commitment to transparency with its stakeholders.
Read more →ORGOINVESTOR PRESENTATION March 2025 FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The
The investor presentation from ORGO discusses forward-looking statements regarding the company's operations, strategies, and the market potential for its products. It highlights the significant risks and uncertainties that could impact future performance, including changes in coverage levels and competition in the market. Key areas of focus include the need for regulatory approvals and the company's commitment to improving patient outcomes through innovative technologies. The presentation underscores the challenges and opportunities present in the market for chronic and acute wounds as well as osteoarthritis.
Read more →ORGO▼ -5.5%on this news· ran to +91% by day 1
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported robust financial results for the fourth quarter and full year ended December 31, 2024, with net revenue rising by 27% in Q4 compared to the same period last year. The company posted a net income of $7.7 million in Q4 2024, marking a strong turnaround from a prior loss. However, annual net income fell to $0.9 million from $4.9 million in 2023, reflecting increased operating expenses. Looking forward, Organogenesis aims to submit the ReNu Biologics License Application by the end of 2025, targeting an unmet need in knee osteoarthritis treatments.
Read more →ORGO▼ -5.5%on this news· ran to +91% by day 1
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
Organogenesis Holdings Inc. reported strong financial results for the fourth quarter of 2024, with net revenue reaching $126.7 million, marking a 27% increase from the previous year. The company also reported a net income of $7.7 million, a turnaround from a loss in the same period last year. Despite these positive results, the total net income for the fiscal year 2024 declined to $0.9 million. Looking ahead, the company plans to submit the ReNu Biologics License Application, which is expected to address an unmet need in treatment for knee osteoarthritis.
Read more →ORGO▲ +5.1%on this news
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
Organogenesis Holdings Inc. has announced that it will report its financial results for the fourth quarter and fiscal year 2024 on February 27, 2025. Following the announcement, the company will conduct a conference call to discuss the results and provide updates. The event highlights Organogenesis's ongoing operations and engagement with investors in the regenerative medicine space.
Read more →ORGOOrganogenesis Expands Manufacturing Capacity to Support Future Growth
Organogenesis Holdings Inc. has announced an expansion of its manufacturing capacity by acquiring a 122,000-square-foot biomanufacturing facility in Smithfield, Rhode Island, to support future growth. This new site will complement the company's existing operations in various locations, including Canton, Massachusetts, and Birmingham, Alabama. The lease agreement is subject to anticipated tax incentives from local and state governments. While the company aims to strengthen its position in the regenerative medicine market, it also faces various risks that may impact its future operations and projections.
Read more →ORGOOrganogenesis Commends Final LCDs
Organogenesis Holdings Inc. has welcomed the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts used in treating diabetic foot ulcers and venous leg ulcers. This coverage will be effective from February 12, 2025, and signifies a move towards recognizing the value of clinical trial data. Organogenesis is optimistic as it offers several products for these conditions, including NuShield, which is now listed as covered. However, the company acknowledges various challenges in maintaining competitiveness and financial stability moving forward.
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported its financial results for the third quarter of 2024, showing a net revenue increase of 6% to $115.2 million compared to the same period last year. The company's net income rose significantly to $12.3 million, indicating strong growth in its Advanced Wound Care segment, which saw a 7% revenue increase. However, adjusted EBITDA declined to $13.4 million, and operating income decreased by 22%. The company has revised its revenue guidance for 2024, projecting growth in the market despite facing rising operating costs.
Read more →ORGOOrganogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company s strategic growth initiatives, enhance balance
Organogenesis Holdings Inc. has announced a $130 million private placement of Series A Convertible Preferred Stock with Avista Healthcare Partners. The company plans to use the proceeds to fund strategic growth initiatives, including clinical development and working capital, as well as repurchase shares of its Class A common stock. Additionally, Garrett Lustig has been appointed to the Board of Directors of Organogenesis, further strengthening its leadership. The financing is viewed positively, offering validation of the company’s growth potential in the regenerative medicine sector.
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
Organogenesis Holdings Inc. reported financial results for the third quarter of 2024, showcasing a net revenue of $115.2 million, increasing by 6% from Q3 2023. Both net income and adjusted net income saw significant improvements, with net income rising to $12.3 million and adjusted net income reaching $12.9 million. However, the company also reported a decrease in adjusted EBITDA and operating income, raising concerns about rising expenses. Looking forward, the company has provided guidance for FY 2024 projecting continued revenue growth, particularly in the Advanced Wound Care segment.
Read more →ORGOOrganogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Organogenesis Holdings Inc. announced a $130 million private placement of Series A Convertible Preferred Stock with Avista Healthcare Partners. The company aims to utilize the net proceeds for various strategic growth initiatives, including debt repayment and repurchasing shares from directors. Additionally, Garrett Lustig has been appointed to the Board, reinforcing the company’s leadership as they pursue their mission in regenerative medicine. The transaction is expected to enhance Organogenesis's balance sheet and overall financial flexibility.
Read more →ORGO▲ +6.7%on this news· ran to +22% by day 3shared move
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. announced a positive interim analysis of its second Phase 3 clinical trial for ReNu, aimed at treating knee osteoarthritis. The independent Data Monitoring Committee confirmed that the trial could proceed without modification after reviewing the interim results on half of the enrolled patients. The positive evaluation includes consistent safety data in line with ReNu's known profile, indicating potential effectiveness as a non-surgical treatment option for knee pain. The trial continues to move forward as part of the company's ongoing development efforts.
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
Organogenesis Holdings Inc. has announced that it will report its third quarter financial results for fiscal year 2024 on November 12, 2024. The report will be disclosed after market close, followed by a conference call at 5:00 p.m. Eastern Time on the same day. The call will cover the financial results as well as provide a corporate update and a Q&A session for participants. Interested individuals can join the live webcast through the company’s website.
Read more →ORGOOrganogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
Organogenesis Holdings Inc. announced the successful results of a randomized controlled trial (RCT) for its product NuShield, intended for the treatment of diabetic foot ulcers (DFUs). In a study involving 218 patients, NuShield demonstrated a statistically superior frequency of wound closure at 12 weeks when compared to standard care. The results are expected to meet Medicare coverage requirements, addressing the higher risks of amputations in diabetic patients, particularly among minority populations. The study's publication in the Journal of Wound Care further solidifies the findings' validity and potential impact on patient care.
Read more →ORGOOrganogenesis Shares ReNu Program Update
Organogenesis Holdings Inc. has announced significant progress in its ReNu development program for knee osteoarthritis. The completion of enrollment for its second Phase 3 clinical trial was accomplished ahead of schedule, with a total of 594 patients participating in the study. Notably, subgroup analysis demonstrated that patients with severe knee osteoarthritis responded similarly to those with moderate disease, supporting the efficacy of ReNu. The company anticipates submitting its Biologics License Application (BLA) to the FDA by the end of 2025.
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported their financial results for the second quarter of 2024, revealing a net revenue increase to $130.2 million, primarily driven by Advanced Wound Care products. Despite the revenue growth, the company reported a significant net loss of $17.0 million, contrasting sharply with the previous year's net income of $5.3 million. Operating losses have also increased, indicating rising expenses, particularly in research and development. The fiscal guidance for 2024 has been reaffirmed, with revenue expectations set between $445 million and $470 million.
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
Organogenesis Holdings Inc. reported its financial results for the second quarter of 2024, showing a net revenue increase to $130.2 million, an 11% rise compared to the same quarter last year. Despite the growth in revenue driven mainly by Advanced Wound Care products, the company encountered a net loss of $17.0 million, a stark contrast to the previous year's net income of $5.3 million. Operating expenses surged by 41%, leading to an operating loss of $13.9 million. The company has reaffirmed its revenue guidance for the year, projecting net revenue between $445 million and $470 million.
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
Organogenesis Holdings Inc. has announced that it will report its financial results for the second quarter of fiscal year 2024 on August 8, 2024, after the market closes. A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Interested participants can access the live webcast or dial in to join the discussion.
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
Organogenesis Holdings Inc. will participate in the Truist Securities MedTech Conference on June 18, 2024, at the InterContinental Boston. The company specializes in regenerative medicine, particularly for advanced wound care and surgical markets. During the conference, management will engage in one-on-one meetings without delivering a formal presentation. This involvement reflects the company's commitment to industry visibility and stakeholder engagement.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
Organogenesis Holdings Inc. reported its financial results for the first quarter of 2024, showing a net revenue of $110.0 million, an increase from $107.6 million in the prior year. The company experienced a net loss reduction to $2.1 million compared to $3.0 million in Q1 2023, although the adjusted net loss increased from $0.7 million to $1.4 million. Revenue from Advanced Wound Care products rose by 3%, while Surgical & Sports Medicine product revenues fell by 9%. Management highlighted optimism for future growth, particularly related to ongoing advancements in the ReNu program and market positioning.
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported financial results for the first quarter of 2024, showing net revenue of $110.0 million, which is a slight increase from $107.6 million in the first quarter of 2023. The company's focus on Advanced Wound Care products led to a 3% revenue increase in that segment, while revenue from Surgical & Sports Medicine products declined by 9%. The company achieved a reduced net loss of $2.1 million, down from $3.0 million in the previous year, although adjusted net loss rose, indicating some operational challenges.
Read more →ORGOOrganogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings announced that its Phase 3 clinical trial for ReNu, a therapy for knee osteoarthritis (OA), achieved its primary endpoint, demonstrating a significant reduction in knee pain and maintenance of function at six months. The trial included 515 patients with moderate to severe OA, who experienced statistically significant improvements compared to the saline control group. The results indicate a favorable safety profile for ReNu, with potential for addressing unmet medical needs in the growing pain management market. Organogenesis plans to discuss the findings with the FDA to advance the product towards commercialization.
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
Organogenesis Holdings Inc. announced that it will report its financial results for the first quarter of fiscal year 2024 after the market closes on May 9, 2024. Following the report, management will host a conference call at 5:00 p.m. ET to discuss the results and provide updates. Participants can access the live webcast or teleconference through the company's website.
Read more →ORGO▲ +6.1%on this news
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
Organogenesis Holdings Inc. announced that the United States District Court for the Eastern District of New York dismissed all claims in a securities fraud case against the company. The court's ruling, granted with prejudice, allows Organogenesis to move forward without the weight of litigation. Chief Administrative and Legal Officer Lori Freedman expressed satisfaction with the decision, emphasizing the company's commitment to enhancing patient outcomes while reducing care costs.
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
Organogenesis Holdings Inc. reported a challenging financial performance for Q4 and fiscal year 2023, recording a 14% decrease in net revenue compared to the previous year. The company faced a net loss in Q4 2023, contrasting with a profit in the same quarter of 2022. Despite these challenges, the CEO expressed optimism for 2024, anticipating a return to revenue growth through product innovation and enhanced customer relationships. The firm is also making strides with its ReNu program targeting knee osteoarthritis treatment.
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance CANTON, Mass., (
Organogenesis Holdings Inc. reported a decline in financial performance for the fourth quarter and fiscal year 2023, with net revenue falling to $99.7 million, a 14% decrease from the previous year. The company posted a net loss of $0.6 million, contrasting sharply with a net income of $7.5 million in Q4 2022. Despite these setbacks, the CEO noted a commitment to restoring revenue growth and introduced guidance for fiscal year 2024, focusing on customer relationships and product development. The company is also making strides with the ReNu program aimed at treating knee osteoarthritis.
Read more →ORGO▼ -5.4%on this news
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Organogenesis Holdings, Inc. for potential claims on behalf of long-term stockholders. This follows a class action complaint alleging that the company improperly billed the federal government. A report from Value Investors Club raised questions about the company's pricing strategies and fiduciary duties. The investigation adds further scrutiny to Organogenesis's operations following a notable drop in stock value.
Read more →ORGO▲ +5.2%on this news
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Organogenesis Holdings Inc. announced its participation in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, taking place in Snowbird, UT on February 13th-14th, 2024. The company will engage in one-on-one meetings on February 14th but will not deliver a formal presentation. This involvement highlights their commitment to the regenerative medicine sector and potential business opportunities. Organogenesis focuses on advanced wound care and sports medicine markets, seeking to showcase innovative solutions.
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
Organogenesis Holdings Inc. has announced that it will report its fourth quarter and fiscal year 2023 financial results on February 29, 2024. The company, which specializes in regenerative medicine, will hold a conference call later that day to discuss these outcomes and provide a corporate update. Participants can join the call through a live webcast or teleconference, with the information available on their investor website.
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. announced its financial results for Q3 2023, reporting net revenues of $108.5 million, a decline from $116.9 million in the previous year. Despite this revenue drop, the company achieved a notable increase in net income, rising to $3.2 million from $0.2 million, alongside a substantial growth in operating income and adjusted EBITDA. Management acknowledged challenges arising from LCD-related issues but expressed optimism for growth momentum going into the end of 2023 with reintroduced financial guidance reflecting ongoing recovery efforts.
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
Organogenesis Holdings Inc. reported its financial results for Q3 2023, noting a net revenue of $108.5 million, which represents a decrease from $116.9 million in Q3 2022. However, the company saw an increase in net income to $3.2 million, up from $0.2 million in the same period last year. Despite challenges related to LCD adoption impacting revenue, the company reported improved operating profitability and cash flow. Looking ahead, Organogenesis projects a slight decrease in annual revenue for 2023, citing ongoing recovery efforts.
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
Organogenesis Holdings Inc. has announced the date for reporting its financial results for the third quarter of fiscal year 2023, set for November 9, 2023. The company will conduct a conference call to discuss these results and provide a corporate update, allowing for a question and answer session afterward. This event will be accessible via a live webcast and will also be archived for future reference.
Read more →ORGO▲ +27.9%on this news
Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS
Organogenesis Holdings Inc. praised the withdrawal of local coverage determinations (LCDs) by three Medicare Administrative Contractors for Skin Substitute Grafts intended for treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. This decision, effective October 1, aims to prevent negative health outcomes including prolonged treatment and amputations. CEO Gary S. Gillheeney emphasized the importance of this outcome for patient care and the support from various stakeholders in challenging the LCDs.
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Organogenesis Holdings Inc. will participate in the Morgan Stanley 21st Annual Global Healthcare Conference held from September 11th-13th in New York City. The company management is scheduled to host a fireside chat on September 11th at 8:00 a.m. Eastern Time to discuss various business matters. This participation underscores Organogenesis's commitment to sharing insights into its regenerative medicine solutions in the advanced wound care and surgical markets.
Read more →ORGO▼ -8.4%on this news· ran to -27% by day 3
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
Organogenesis Holdings Inc. reported a decline in net revenue and net income in its second quarter results for 2023 compared to the same quarter in 2022. The company has withdrawn its fiscal year 2023 guidance due to uncertainties arising from new local coverage determinations that limit product coverage for diabetic foot ulcers and venous leg ulcers. Despite some areas of performance exceeding expectations, the decrease in both revenue and income highlights significant challenges the company is facing in the current market environment.
Read more →ORGO▼ -8.4%on this news· ran to -27% by day 3
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance CANTON, Mass., (
Organogenesis Holdings Inc. announced a decline in financial performance for the second quarter of 2023, with net revenue dropping to $117.3 million, down from $121.4 million the previous year. The company is withdrawing its fiscal year 2023 guidance due to uncertainties arising from new local coverage determinations that could affect the treatment of diabetic foot ulcers and venous leg ulcers. Despite some positive remarks about exceeding revenue expectations in Q2, the overall outlook remains unclear as management engages with authorities regarding product coverage.
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023
Organogenesis Holdings Inc. has announced that it will report its financial results for the second quarter of fiscal year 2023 on August 9, 2023, after market closure. The announcement includes plans for a conference call at 5:00 p.m. ET on the same day, in which management will discuss the quarterly results and provide updates. Participants will have options for accessing the live webcast or teleconference.
Read more →ORGO▼ -5.4%on this news· ran to +43% by day 3
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
Organogenesis Holdings Inc. reported its first quarter 2023 financial results, revealing a net revenue of $107.6 million, an increase of $10.5 million over the previous year. The growth was primarily driven by a 12% increase in sales of Advanced Wound Care products; however, the company also recorded a net loss of $3.0 million, a significant rise from the $0.9 million loss experienced in the same period last year. Despite the increased losses, the company raised its financial guidance for the year, reflecting optimism about their performance in the Advanced Wound Care market.
Read more →ORGO▼ -5.4%on this news· ran to +43% by day 3
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. reported its financial results for the first quarter of 2023, showcasing a net revenue growth of 11% to $107.6 million. Advanced Wound Care products showed strong performance with a 12% revenue increase, while Surgical & Sports Medicine recorded a slight decline of 4%. The company noted an increased net loss of $3 million for the quarter, compared to a loss of $0.9 million in the same quarter of the previous year. Despite the increase in losses and operating expenses, the company is optimistic about its market position and has raised its 2023 financial guidance based on the positive quarterly results.
Read more →ORGOOrganogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors
Organogenesis Holdings Inc. announced the election of Gary S. Gillheeney, Sr. as Chair of the Board of Directors, while he continues as CEO. This change follows the tenure of Alan A. Ades, who remains a Board member. The company highlights a commitment to its growth strategy and integrated healing solutions in the Advanced Wound Care and Sports Medicine markets. The Board's choice reflects confidence in Gillheeney's leadership to guide the company into its next growth phase.
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023
Organogenesis Holdings Inc. announced that it will report its first quarter financial results for fiscal year 2023 after the market closes on May 10, 2023. The company, which specializes in regenerative medicine solutions for advanced wound care and surgical markets, will also host a conference call at 5:00 p.m. Eastern Time to discuss the results and provide updates. Stakeholders are encouraged to participate in the call and access the live webcast available on the company's website.
Read more →ORGOOrganogenesis Applauds Findings from the Office of Inspector General
Organogenesis Holdings Inc. commended the U.S. Department of Health and Human Services' Office of Inspector General for its report suggesting that adopting average sales price (ASP) payments for all skin substitute products could significantly reduce Medicare Part B costs. The report indicates that if the Centers for Medicare and Medicaid Services uniformly implemented this payment methodology, it could save considerable amounts quarterly. The CEO of Organogenesis highlighted this transition as a means to improve access to efficacy-driven therapies and stabilize the market.
Read more →ORGO▼ -6.9%on this news
Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance CANTON, Mass., (
Organogenesis Holdings Inc. reported its fourth quarter and fiscal year 2022 financial results, which show a decline in net revenue and net income compared to the previous year. The company experienced a 10% decrease in revenue for Q4 and a 4% decrease for the full year, particularly impacting its Advanced Wound Care and Surgical & Sports Medicine products. Despite these challenges, management provided optimistic guidance for FY 2023, anticipating growth in hospital outpatient settings and continued efforts to improve their competitive position.
Read more →ORGO▼ -6.9%on this news
Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance
Organogenesis Holdings Inc. reported a challenging fiscal performance for Q4 and the entire year 2022. Key financial metrics showed a notable decline, with Q4 net revenue decreasing by 10% to $115.5 million and net income falling sharply to $7.5 million from $51 million in the previous year. This trend continued into the fiscal year, with total net revenue of $450.9 million, down 4% compared to 2021. Despite these setbacks, the company highlighted growth opportunities in hospital outpatient settings for 2023.
Read more →ORGO▼ -6.9%on this news
Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. announced positive results from the interim analysis of its Phase 3 clinical trial for ReNu, aimed at treating knee osteoarthritis. The Independent Data Monitoring Committee found the results encouraging and recommended the trial continue without changes. The study involves 516 patients and assesses pain reduction after administration of ReNu compared to a saline control. The favorable outcomes come as the demand for effective knee osteoarthritis treatments continues to grow.
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023
Organogenesis Holdings Inc. announced that it will report its fourth-quarter and fiscal year 2022 financial results on March 1, 2023, after the market closes. A conference call is scheduled for the same day at 5:00 p.m. Eastern Time to discuss the results and provide a corporate update. The event highlights the company's ongoing commitment to transparency with its stakeholders.
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results CANTON, Mass., (November 9, 2022) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions f
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022
CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGO▼ -6.5%on this news· ran to -27% by day 3
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGO▼ -6.5%on this news· ran to -27% by day 3
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results CANTON, Mass., (August 9, 2022) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022
CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine marke
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2022 Financial Results CANTON, Mass., (
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results CANTON, Mass., (May 10, 2022) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the
Read more →ORGO▼ -8.8%on this news· ran to -25% by day 3shared move
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors CANTON, Mass., May 5, 2022 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solu
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGO▼ -5.3%on this news
Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference
CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance CANTON, Mass., (
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance CANTON, Mass., (March 1, 2022) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufac
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance
CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGO▼ -12%on this news
Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors
Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors CANTON, Mass., February 17, 2022 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for t
Read more →ORGOOrganogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February
CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022
CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Organogenesis Holdings, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Organogenesis Holdings, Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO) in the United
Read more →ORGOORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Organogenesis Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO) on behalf of Organogenesis stockh
Read more →ORGOOrganogenesis Appoints Prathyusha Duraibabu to Board of Directors
Organogenesis Appoints Prathyusha Duraibabu to Board of Directors CANTON, Mass., November 22, 2021 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Adv
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results CANTON, Mass. (November 9, 2021) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results
CANTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the Credit Suisse 30th Annual Healthcare Conference
CANTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOORGANOGENESIS INVESTIGATION: Block & Leviton Is Investigating Organogenesis Holdings, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Organogenesis Holdings, Inc. (NASDAQ: ORGO) for potential securities law violations. Investors who have lost money in their Organogenesis Holdings, Inc. investment should contact the firm to learn more abo
Read more →ORGOOrganoGenesis Holdings Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises OrganoGenesis Holdings ("OrganoGenesis" or the "Company") (NASDAQ: ORGO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of inv
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021
CANTON, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results CANTON, Mass. (August 9, 2021) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results
CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank
CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021
CANTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOCORRECTING and REPLACING Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
CORRECTING and REPLACING Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine marke
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass. (May 10, 2021) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021
CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance
CANTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance CANTON, Mass. (
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance CANTON, Mass. (March 16, 2021) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufa
Read more →ORGOOrganogenesis Appoints David C. Francisco as Chief Financial Officer
Organogenesis Appoints David C. Francisco as Chief Financial Officer CANTON, Mass., February 16, 2021 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the
Read more →ORGOOrganogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March
CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021
CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 CANTON, Mass. (
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 CANTON, Mass. (January 13, 2021) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercial
Read more →ORGOOrganogenesis Holdings Inc. to Participate in the ICR Conference 2021
CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOForward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our" refer to Organogenesis Holdings Inc. (
Corporate Presentation December 2020 STRICTLY CONFIDENTIAL Exhibit 99.1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our" refer to Organogenesis
Read more →ORGOOrganogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
CANTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results CANTON, Mass. (November 9, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of produc
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020
CANTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 CANTON, Mass. (
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 CANTON, Mass. (October 14, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of produc
Read more →ORGOOrganogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGOCorporate Presentation September 2020 1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our
0 Exhibit 99.1 Corporate Presentation September 20200 Exhibit 99.1 Corporate Presentation September 2020 1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us
Read more →ORGOOrganogenesis Holdings Inc. Announces Management Change CANTON, Mass. (
Organogenesis Holdings Inc. Announces Management Change CANTON, Mass. (August 24, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound
Read more →ORGOOrganogenesis Holdings Inc. Announces Management Change
CANTON, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results CANTON, Mass. (August 10, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results
CANTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 CANTON, Mass. (
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 CANTON, Mass. (July 15, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product so
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020
CANTON, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2020 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results CANTON, Mass. (May 11, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2020 Financial Results
CANTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine marke
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call CANTON, Mass. (April 8, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative m
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020
Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call CANTON, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commerc
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance CANTON, Mass. (
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance CANTON, Mass. (March 9, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development,
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance
CANTON, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
Read more →ORGOOrganogenesis Holdings Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
CANTON, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 9, 2020
CANTON, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019
CANTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019 CANTON, Mass. (
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019 CANTON, Mass. (January 13, 2020) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commerci
Read more →ORGOUnless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our" refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporati
Corporate Presentation December 2019 Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our" refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation. References in th
Read more →ORGOOrganogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock CANTON, Mass., (
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock CANTON, Mass., (November 19, 2019) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of produc
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results CANTON, Mass. (November 12, 2019) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr
Read more →ORGOOrganogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results
CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019
CANTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGOOrganogenesis Announces Completion of Exchange Offer and Plan to Exchange Remaining Outstanding Public Warrants CANTON, MASSACHUSETTS (
Organogenesis Announces Completion of Exchange Offer and Plan to Exchange Remaining Outstanding Public Warrants CANTON, MASSACHUSETTS (August 19, 2019) Organogenesis Holdings Inc. (Nasdaq: ORGO) (the Company ) announced today the completion of its previously announced exchange
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results CANTON, Mass. (August 9, 2019) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product
Read more →ORGOOrganogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results
CANTON, Mass., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark
Read more →ORGOOrganogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation
CANTON, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO) (the “Company,” “we” or “our”) today announced that it has commenced an offer to exchange (“Offer to Exchange”) 0.095 shares of the Company’s Class A common stock (“Class A Common Stock”)
Read more →ORGOOrganogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2019 Financial Results on August 9, 2019
CANTON, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2019 Financial Results CANTON, Mass. (
Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results CANTON, Mass. (May 10, 2019) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the
Read more →ORGOOrganogenesis Holdings Inc. Reports First Quarter 2019 Financial Results
CANTON, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine marke
Read more →ORGOOrganogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019
CANTON, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGOOrganogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results
CANTON, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine
Read more →ORGOOrganogenesis Holdings Inc. Announces ReNu Clinical Trial Results at AAOS 2019 Annual Meeting
CANTON, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOOrganogenesis Holdings Inc. to Present at Oppenheimer’s 29th Annual Healthcare Conference
CANTON, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine m
Read more →ORGOOrganogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019
CANTON, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine ma
Read more →ORGOReport of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders Organogenesis Inc., Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of O
Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Organogenesis Inc. (the Company) as of December 31, 2017 and 2016, the related
Read more →ORGOCONFIDENTIAL FOR IMMEDIATE RELEASE AVISTA HEALTHCARE PUBLIC ACQUISITION CORP. TO COMBINE WITH ORGANOGENESIS INC. New York, NY and Canton, MA
AVISTA HEALTHCARE PUBLIC ACQUISITION CORP. TO COMBINE WITH ORGANOGENESIS INC. New York, NY and Canton, MA, August 17, 2018 Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA) ( AHPAC ), a publicly traded special purpose acquisition company, and Organogenesis Inc. ( Organo
Read more →ORGOInvestor December Presentation 2017 2017 Envigo Disclaimer This presentation (the Presentation ) has been prepared solely for, and is being delivered on a confidential basis to, persons considering a possible business re
Investor December Presentation 2017 2017 Envigo Disclaimer This presentation (the Presentation ) has been prepared solely for, and is being delivered on a confidential basis to, persons considering a possible business relationship with Avista Heathcare Public Acquisition Corp. (
Read more →ORGOCONFIDENTIAL AVISTA HEALTHCARE PUBLIC ACQUISITION CORP. TO COMBINE WITH ENVIGO INTERNATIONAL HOLDINGS, INC. Merged entity to be listed on the NASDAQ East Millstone, NJ and New York, NY
AVISTA HEALTHCARE PUBLIC ACQUISITION CORP. TO COMBINE WITH ENVIGO INTERNATIONAL HOLDINGS, INC. Merged entity to be listed on the NASDAQ East Millstone, NJ and New York, NY, August 21, 2017 Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA) ( AHPAC ), a publicly traded s
Read more →ORGOAvista Healthcare Public Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing
Avista Healthcare Public Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing November 29, 2016 NEW YORK, NY, November 28, 2016 Avista Healthcare Public Acquisition Corp. (NASDAQ:AHPAU) (the Company ) announced that Credit Suis
Read more →ORGOAVISTA HEALTHCARE PUBLIC ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet F-3 Notes to Balance Sheet F-4 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUN
AVISTA HEALTHCARE PUBLIC ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Audit Committee of the Board of Directo
Read more →ORGOAvista Healthcare Public Acquisition Corp. Announces Pricing of $300,000,000 Initial Public Offering
Avista Healthcare Public Acquisition Corp. Announces Pricing of $300,000,000 Initial Public Offering NEW YORK, NY, October 10, 2016 Avista Healthcare Public Acquisition Corp. (the Company ), a blank check company formed for the purpose of entering into a merger, share exchange,
Read more →ORGOOrganogenesis, Neurobiological Technologies and Insilco Holding Events to be Broadcast by Vcall Over the Internet
RICHMOND, Va., Nov. 9, 2001 (PRIMEZONE) -- Organogenesis Inc. (AMEX:ORG), Neurobiological Technologies, Inc. (Nasdaq:NTII) and Insilco Holding Co. (OTCBB:INSL) will broadcast their investor communication events over the Internet, Vcall, a Service of World Investor Link announced
Read more →Competitive Position
How ORGO ranks across every disease it competes inCompetitive Position is a premium feature
See how ORGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial